Cenix Expands AstraZeneca Agreement | GenomeWeb

NEW YORK (GenomeWeb News) – Cenix Bioscience said today that it has expanded an oncology drug research agreement with AstraZeneca to include RNAi-based studies for respiratory and inflammation-related conditions.

Under the new agreement, which expands upon a deal announced in March, Cenix will complete at least three projects using its RNAi gene silencing technology as well as image analysis using Definiens’ Cellenger platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.